index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

94

 

NOTICES

156

 

 

MOTS CLES

Quality of life Amyloidosis Psoriasis Auto-immune hepatitis Auto-Diagnostic Cardiomyopathy Anti-HCV Direct Acting Antivirals DAA Graft-versus-host disease Ustekinumab Cardiotoxicity Biologic drug Spondyloarthritis Alitretinoin Atopic dermatitis Adolescent Biologic Psoriatic arthritis Méta-Analyse Infliximab Burden Immunotherapy Antibiotic resistance Intensive care Drug survival Adverse side effects Biologic therapy Antimicrobiens Biosimilar Pharmaceuticals Pharmacovigilance Meta-Analysis Angiotensin-converting enzyme inhibitors Atrial fibrillation Apre-milast Etanercept Access to care ASDAS Biologics Bacterial rhinosinusitis Apremilast Biological therapy Albinism Anxiety Adalimumab Abus d'antibiotiques Epidemiology Addiction Autoimmunity Alcohol Sacroiliitis Cardio-oncology Antibiotics Biological Therapy Endocrine toxicity Primary adrenal insufficiency COVID-19 Spondylitis Arrhythmia Axial spondyloarthritis Cancer Acute Myeloid Leukaemia AML Placebo Treatment Glucocorticoids Dermatology Azathioprine Arthritis Immune-related adverse events Vigibase® Pharmacoepidemiology Antimicrobial Stewardship Ankylosing Network meta-analysis Accelerometer Pregnancy Drug reaction Antimicrobials Antibiotic misuse BTK protein Angiotensin receptor blockers Autoimmune diseases Prostate cancer Immune checkpoint inhibitors Stability Ethics Bacterial Aging Management Anticancer drugs Biomarkers Biomédicaments ArtThese Sipuleucel-T Pharmaco-Épidémiologie Anti-TNF Anti-Bacterial Agents Antimicrobial resistance Anxiété Systematic review Ankylosing spondylitis Beta-lactam antibiotics

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS